Clinical trial
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That…
NCT00005645 · Genzyme, a Sanofi Company, Industry · Withdrawn
Key facts
| NCT number | NCT00005645 |
|---|---|
| Title | ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment |
| Official title | Phase II Trial of ILX295501 Administered Orally Once Weekly x 3 Repeated Every 6 Weeks in Patients With Stage III/IV Ovarian Cancer |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | ILX-295501 |
| Enrollment | 0 |
| Start date | May 1, 1999 |
| First posted | May 26, 2004 |
| Last update posted | Sep 18, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: